EPCAM and neoplasm: In a clinical cohort of patients with stages III and IV metastatic breast cancers, by using EpCAM as a marker for EMT, the loss of epithelial phenotype in CTCs has been demonstrated, while bone marrow-derived disseminated tumor cells retained an epithelial phenotype [118].